NCT03214666 2022-11-10
GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies
GT Biopharma, Inc.
Phase 1/2 Terminated
GT Biopharma, Inc.
Novartis
Stanford University
Novartis
Stanford University
M.D. Anderson Cancer Center